Real-Time Regulatory Intelligence for Biotech
Built for compliance teams, regulatory affairs professionals, and biotech investors. BioIntel.io monitors FDA, FTC, clinical trials, and funding signals — delivering instant risk scoring, claim analysis, and technology momentum intelligence.
Regulatory Pressure
Stem Cell Clinic Enforcement Rising
Therapeutic Momentum
Exosome Therapies Accelerating
Clinical Pipeline
RNA Therapeutics Phase II Expansion
Research Velocity
Senolytics Publication Surge
Capital Flows
Cell Therapy Venture Funding
How It Works
From raw claim to regulatory clarity in seconds
Paste Your Claim
Enter any marketing claim, product label text, or advertising copy. BioIntel accepts raw text from any biotech or supplement context.
Get Instant Risk Scoring
Our engine checks against 50+ regulatory frameworks including FDA, FTC, DSHEA, and 21 CFR. Every flag cites the specific regulation.
Fix With Safer Language
Receive compliant alternatives for every flagged phrase. Export reports for your legal team, or share directly with your marketing department.
Signature Feature
Technology Momentum Index
A composite score ranking emerging biotech technologies by research velocity, clinical trial activity, venture funding, regulatory signals, and startup formation. Updated continuously.
Scores computed from research, clinical, funding, regulatory, and startup signals
Platform Capabilities
Full-spectrum regulatory intelligence
From claim screening to technology scouting, BioIntel.io covers the entire compliance and intelligence workflow.
Claim Analysis
Paste any marketing claim and get instant risk scoring against FDA, FTC, DSHEA, and 50+ regulatory frameworks.
Technology Momentum Index
Track emerging biotech technologies with composite momentum scores drawn from research, trials, funding, and regulatory signals.
Real-Time Signals
Live intelligence signals from FDA, FTC, ClinicalTrials.gov, PubMed, and funding sources — analyzed and scored in seconds.
Regulatory Context
Every flag cites the specific regulation — 351(a) BLA, 21 CFR 1271, FTC Act Section 5, DSHEA, and more.
Document Audits
Upload product labels, marketing materials, or website copy for full compliance audits with exportable reports.
Safer Language Engine
Get compliant alternative phrasing for every flagged claim. Share suggestions directly with your marketing and legal teams.
Sample Output
See what BioIntel catches
Here is a real example of how BioIntel analyzes marketing claims and delivers actionable compliance intelligence.
Input Claim
"Our stem cell therapy has been clinically proven to reverse aging and cure chronic inflammation in 95% of patients."
"clinically proven to reverse aging"
Violates FTC Act Section 5 and FDA 21 CFR 101.93 — unsubstantiated disease/aging claims require rigorous clinical evidence.
Safer Alternative
"May support cellular health based on preliminary research"
"cure chronic inflammation"
Disease cure claims are prohibited for supplements under DSHEA. Only FDA-approved drugs may claim to cure diseases.
Safer Alternative
"Supports a healthy inflammatory response"
"95% of patients"
Specific efficacy percentages require substantiation from adequate and well-controlled clinical trials per FTC guidelines.
Safer Alternative
"Participants in our study reported positive outcomes"
Ready to see what others miss?
Join compliance teams, investors, and biotech operators using BioIntel.io for regulatory intelligence that moves at the speed of the industry.